A Phase I Open-label Dose-escalation Study With Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma.
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2015
At a glance
- Drugs Lenalidomide; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions
- 28 Aug 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 May 2011 New trial record